ClinicalTrials.gg

Program

Temozolomide

Also written as “temozolomide”, “Temozolomide (TMZ)” and “TMZ”.

Its studies are mostly in Glioblastoma · Glioma · Sarcoma, Ewing · Melanoma · Carcinoma, Non-Small-Cell Lung, led by 13 companies.

Furthest: phase 4, since May 27, 200834 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck150 open or runningphase 4since May 27, 2008May 1, 2002none ahead
Eli Lilly42 open or runningphase 2since Oct 12, 2010Oct 12, 2010May 2027phase 2 · NCT05999994
Hoffmann-La Roche20 open or runningphase 2since Apr 30, 2010Apr 30, 2010none ahead
Leaf Vertical20 open or runningphase 2since Jun 5, 2018Jun 5, 2018none ahead
Orphelia Pharma20 open or runningphase 1since Mar 27, 2020Mar 27, 2020none ahead
SynerGene Therapeutics20 open or runningphase 2since Dec 18, 2014Dec 18, 2014none ahead
Bristol-Myers Squibb10 open or runningphase 1since Sep 7, 2016Sep 7, 2016none ahead
CASI Pharmaceuticals10 open or runningphase 2since May 30, 2007May 30, 2007none ahead
monte-verde-sa10 open or runningphase 4since Jan 7, 2015Jan 7, 2015none ahead
monteris-medical10 open or runningphase 1since Aug 18, 2016Aug 18, 2016none ahead
NovoCure10 open or runningno phasesince Dec 18, 2018Dec 18, 2018none ahead
vion-pharmaceuticals10 open or runningphase 1since Dec 7, 2004Dec 7, 2004none ahead
zsky-biotech-inc11 open or runningphase 2since Jan 5, 2026Jan 5, 2026Dec 24, 2028phase 2 · NCT07365280

Also a collaborator on its studies: triphase-research-and-development-iii-corp, aesca-pharma-gmbh and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since May 1, 2002.

  1. Dec 18, 2014SynerGene Therapeutics's first study: phase 2 study in GlioblastomaNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02340156 · 1 enrolled · United States, Taiwan
  2. Jan 7, 2015monte-verde-sa's first study: phase 4 study in Brain NeoplasmsNew to monte-verde-samonte-verde-sa · NCT02343081 · 24 enrolled · Argentina
  3. Aug 18, 2016monteris-medical's first study: phase 1 study in GlioblastomaNew to monteris-medicalmonteris-medical · NCT02880410 · 3 enrolled · United States
  4. Sep 7, 2016Bristol-Myers Squibb's first study: phase 1 study in GlioblastomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02903069 · 66 enrolled · United States, Canada, Switzerland
  5. May 17, 2018Early phase 1 study in Central Nervous System NeoplasmsSynerGene Therapeutics · NCT03554707 · United States
  6. Jun 5, 2018Leaf Vertical's first study: phase 2 study in Pancreatic NeoplasmsNew to Leaf VerticalLeaf Vertical · NCT03607643 · 160 enrolled · United States
  7. Aug 22, 2018Phase 1 study in GlioblastomaLeaf Vertical · NCT03687034 · 21 enrolled
  8. Dec 18, 2018NovoCure's first study: no phase study in GlioblastomaNew to NovoCureNovoCure · NCT03780569 · 10 enrolled · Israel
  9. Jan 22, 2020Phase 2 study in Sarcoma, EwingEli Lilly · NCT04238819 · 47 enrolled · United States, Australia, Belgium and more
  10. Mar 27, 2020Orphelia Pharma's first study: phase 1 study in Therapeutic EquivalencyNew to Orphelia PharmaOrphelia Pharma · NCT04467346 · 36 enrolled · France
  11. Oct 20, 2020Phase 1 study in NeoplasmsOrphelia Pharma · NCT04610736 · 49 enrolled · France, Germany, Netherlands and more
  12. Jun 28, 2022Phase 2 study in Sarcoma, EwingEli Lilly · NCT05440786 · 46 enrolled · United States, Australia, France and more
  13. Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
  14. Jan 5, 2026zsky-biotech-inc's first study: phase 2 study in GlioblastomaNew to zsky-biotech-inczsky-biotech-inc · NCT07365280 · 78 planned

Ahead

  1. May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
  2. Dec 24, 2028Primary completion: phase 2 study in Glioblastomazsky-biotech-inc · NCT07365280

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07365280Glioblastoma2Not yet recruitingzsky-biotech-incDec 24, 202878
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingEli LillyMay 2027105
NCT05440786Sarcoma, Ewing · United States, Australia, France and more2Active, not recruitingEli LillyJan 15, 202546
NCT04610736Neoplasms · France, Germany, Netherlands and more1CompletedOrphelia PharmaJan 15, 202349
NCT04467346Therapeutic Equivalency · France1CompletedOrphelia PharmaDec 17, 202136
NCT04238819Sarcoma, Ewing · United States, Australia, Belgium and more2CompletedEli LillyMar 15, 202447
NCT03780569Glioblastoma · Israel–UNKNOWNNovoCureJan 201910
NCT03687034Glioblastoma1UNKNOWNLeaf VerticalSep 30, 201921
NCT03607643Pancreatic Neoplasms · United States2UNKNOWNLeaf VerticalJun 30, 2020160
NCT03554707Central Nervous System Neoplasms · United StatesEarly 1WithdrawnSynerGene TherapeuticsJun 1, 20220
NCT02903069Glioblastoma · United States, Canada, Switzerland1CompletedBristol-Myers SquibbJan 25, 202166
NCT02880410Glioblastoma · United States1Terminatedmonteris-medicalSep 14, 20183
NCT02343081Brain Neoplasms · Argentina4Completedmonte-verde-saOct 201324
NCT02340156Glioblastoma · United States, Taiwan2TerminatedSynerGene TherapeuticsNov 20181
NCT01860638Glioblastoma · Austria, Bulgaria, Canada and more2CompletedHoffmann-La RocheJan 13, 2017296
NCT01220271Glioma · United States, Germany, Spain2CompletedEli LillyAug 201575
NCT01115491Glioblastoma · Spain2CompletedHoffmann-La RocheJul 201232
NCT00831545Melanoma2CompletedMerckOct 20, 2006162
NCT00783393Astrocytoma2CompletedMerckJun 17, 200532
NCT00687323Leukemia, Myeloid, Acute2CompletedMerckMay 9, 201147
NCT00686725Glioblastoma4CompletedMerckSep 28, 201199
NCT00684567Glioblastoma2CompletedMerckOct 31, 200730
NCT00632203Carcinoma, Non-Small-Cell Lung2TerminatedMerckJan 6, 201153
NCT00638963Breast Neoplasms2TerminatedMerckJun 30, 20106
NCT00481455Glioblastoma · United States2CompletedCASI PharmaceuticalsSep 200715
NCT00424554Glioma2CompletedMerckJan 11, 201040
NCT00423150Colorectal Neoplasms2TerminatedMerckJun 11, 200986
NCT00392171Glioma2CompletedMerckSep 15, 2009120
NCT00335075Glioblastoma3CompletedMerckFeb 23, 2006151
NCT00266812Carcinoma, Non-Small-Cell Lung2TerminatedMerckJan 16, 200835
NCT00098436Leukemia · United States1Completedvion-pharmaceuticalsOct 200625
NCT00091572Melanoma3CompletedMerckDec 31, 2007859
NCT00076856Carcinoma, Non-Small-Cell Lung2CompletedMerckMar 31, 200695
NCT00034697Neoplasm Metastasis2TerminatedMerckJan 30, 200324

How it is read

Names in the registry

  • “Temozolomide”, 37 entries
  • “temozolomide”, 11 entries
  • “Temozolomide (TMZ)”, 3 entries
  • “TMZ”, 2 entries
  • “Olutasidenib + TMZ”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.